{
  "metadata": {
    "case_id": 31,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T15:44:41.638948",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/31_NCT04358549.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/31_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.94,
          0.25
        ],
        [
          0.45,
          0.92
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "label": "Favipiravir Treatment Arm",
            "type": "EXPERIMENTAL",
            "description": "Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2-14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2-14: 800 mg BID plus SOC",
            "interventionNames": [
              "Drug: Favipiravir"
            ]
          },
          "pred_item": {
            "label": "Favipiravir plus Standard of Care",
            "type": "EXPERIMENTAL",
            "description": "Hospitalized adults with PCR-confirmed COVID-19 randomized to receive oral favipiravir in addition to site standard of care. Patients received 1800 mg favipiravir per os twice daily on day 1, followed by 1000 mg twice daily for 13 additional days (total planned duration 14 days). For patients with Child-Pugh A liver disease, the maintenance dose was reduced to 800 mg twice daily. For patients unable to swallow, tablets were crushed and administered as a slurry via nasogastric tube. Treatment continued after discharge, with total follow-up of 46 days after the active treatment phase.",
            "interventionNames": [
              "Favipiravir",
              "Standard of Care"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "label": "Standard of Care Arm",
            "type": "OTHER",
            "description": "Standard of Care for 14 days",
            "interventionNames": [
              "Other: Standard of Care"
            ]
          },
          "pred_item": {
            "label": "Standard of Care Alone",
            "type": "ACTIVE_COMPARATOR",
            "description": "Hospitalized adults with PCR-confirmed COVID-19 randomized to receive site standard of care alone, without favipiravir. Standard of care initially excluded other antivirals (including remdesivir), systemic steroids >10 mg prednisone equivalent, immune plasma, or other immunosuppressive/immunomodulatory drugs; beginning in July 2020, dexamethasone 6 mg daily was permitted following RECOVERY trial results.",
            "interventionNames": [
              "Standard of Care"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.98,
          0.15
        ],
        [
          0.3,
          0.86
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Favipiravir",
            "description": "Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets",
            "armGroupLabels": [
              "Favipiravir Treatment Arm"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Favipiravir",
            "description": "Oral antiviral nucleoside analog active against a broad spectrum of RNA viruses, including SARS-CoV-2. In this study, the dosing regimen was 1800 mg by mouth twice daily on day 1, followed by 1000 mg by mouth twice daily on days 2–14 (maintenance dose reduced to 800 mg twice daily for patients with Child-Pugh A liver disease). Tablets could be crushed and given as a slurry via nasogastric tube in patients unable to swallow. Planned duration of therapy was 14 days, continued after hospital discharge.",
            "armGroupLabels": [
              "Favipiravir plus Standard of Care"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "type": "OTHER",
            "name": "Standard of Care",
            "description": "Standard of Care for individual study site as determined by each hospital's protocol",
            "armGroupLabels": [
              "Standard of Care Arm"
            ]
          },
          "pred_item": {
            "type": "OTHER",
            "name": "Standard of Care",
            "description": "Supportive and institutional standard management for hospitalized adults with COVID-19 at participating US academic medical centers. At enrollment, concomitant use of other antivirals (including remdesivir), systemic steroids (except topical/inhaled or ≤10 mg prednisone equivalent), immune plasma, and other immunosuppressive or immunomodulatory drugs was not allowed. From July 2020 onward, dexamethasone 6 mg daily was permitted per evolving treatment guidelines.",
            "armGroupLabels": [
              "Favipiravir plus Standard of Care",
              "Standard of Care Alone"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.82
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "measure": "Time to Viral Clearance",
            "description": "To determine the effect of favipiravir + SOC v. SOC on viral clearance of COVID-19 as measured by nasopharyngeal and oropharyngeal sampling",
            "timeFrame": "Day 29"
          },
          "pred_item": {
            "measure": "Time to viral clearance",
            "description": "Time in days from randomization to first negative or below lower limit of quantification SARS-CoV-2 RT-PCR result from scheduled nasopharyngeal and oropharyngeal swabs, without any subsequent positive result.",
            "timeFrame": "Up to day 29"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 15,
      "similarity_matrix": [
        [
          0.95,
          0.72,
          0.62,
          0.1,
          0.4,
          0.3,
          0.32,
          0.42,
          0.32,
          0.25,
          0.25,
          0.3,
          0.21,
          0.25,
          0.12
        ],
        [
          0.7,
          0.78,
          0.78,
          0.12,
          0.3,
          0.3,
          0.19,
          0.35,
          0.32,
          0.12,
          0.1,
          0.25,
          0.05,
          0.08,
          0.05
        ],
        [
          0.05,
          0.08,
          0.1,
          0.02,
          0.08,
          0.08,
          0.05,
          0.08,
          0.05,
          0.08,
          0.18,
          0.08,
          0.25,
          0.18,
          0.82
        ],
        [
          0.05,
          0.07,
          0.08,
          0.1,
          0.08,
          0.05,
          0.03,
          0.05,
          0.1,
          0.08,
          0.18,
          0.1,
          0.2,
          0.3,
          0.9
        ],
        [
          0.02,
          0.1,
          0.1,
          0.05,
          0.02,
          0.05,
          0.05,
          0.05,
          0.05,
          0.05,
          0.38,
          0.05,
          0.2,
          0.2,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "measure": "Status of Clinical Recovery as Measured by the Study-specific 6-point Ordinal Scale",
            "description": "To determine the clinical benefit of administering favipiravir plus SOC compared to SOC alone, clinical benefit will be measured using a study-specified ordinal scale on Day 15 in adult patients hospitalized with COVID-19.",
            "timeFrame": "on Day 15"
          },
          "pred_item": {
            "measure": "Status of clinical recovery on 6-point ordinal scale",
            "description": "Clinical status assessed using a study-specific 6-point ordinal scale, capturing levels of hospitalization and respiratory support.",
            "timeFrame": "Day 15; also assessed on days 1, 2, 3, 8, 11, 15, 29, and 45 and up to day 60 when possible"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "measure": "Time to the National Early Warning Score 2 (NEWS2) of 2 or Less, or Hospital Discharge",
            "description": "The NEWS2 is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, temperature. The time to aggregate NEWS2 score of ≤ 2 (sustained for at least 72 hours) or hospital discharge is analyzed.",
            "timeFrame": "through Day 29"
          },
          "pred_item": {
            "measure": "Time to clinical recovery",
            "description": "Time from initiation of study treatment until normalization of fever, respiratory rate, and oxygen saturation and alleviation of cough sustained for at least 72 hours, or discharge. Normalization and alleviation defined as fever ≤37.2°C (oral), respiratory rate ≤24/min on room air, SpO2 >94% on room air, and cough rated mild or absent on a patient-reported scale.",
            "timeFrame": "Up to day 29"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 12,
          "score": 0.25,
          "status": "matched",
          "ref_item": {
            "measure": "Characterize the Pharmacokinetics (PK) of Favipiravir in Plasma: Cmax",
            "description": "Measurement of maximum plasma concentration",
            "timeFrame": "through Day 14"
          },
          "pred_item": {
            "measure": "Safety of favipiravir plus standard of care vs standard of care alone",
            "description": "Incidence, type, and severity of treatment-emergent adverse events and serious adverse events.",
            "timeFrame": "From first dose through day 60 follow-up"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 14,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Characterized the Pharmacokinetics (PK) of Favipiravir in Plasma: Cmin",
            "description": "Measurement of minimum plasma concentration",
            "timeFrame": "through Day 14"
          },
          "pred_item": {
            "measure": "Population pharmacokinetics of favipiravir",
            "description": "Favipiravir pharmacokinetic parameters including maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), and AUC(0–24h).",
            "timeFrame": "Days 1, 2, 8, and 14"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 10,
          "score": 0.38,
          "status": "matched",
          "ref_item": {
            "measure": "Characterized the Pharmacokinetics (PK) of Favipiravir in Plasma: Area Under Curve (AUC 0-24)",
            "description": "Measurement of the area under the curve of plasma concentration versus time profile",
            "timeFrame": "through Day 14"
          },
          "pred_item": {
            "measure": "Change in SARS-CoV-2 viral load in upper respiratory tract",
            "description": "Change in SARS-CoV-2 viral load in upper respiratory tract specimens as assessed by area under the viral load curve.",
            "timeFrame": "Up to day 29"
          }
        }
      ]
    }
  ]
}